The Motley Fool

4 Ways GlaxoSmithKline plc Will Continue To Lag The Biotechnology Sector

Right now I’m comparing some of the most popular companies in the FTSE 100 with their sector peers in an attempt to establish which one is the more attractive investment.

Today I’m looking at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!


Firstly, let’s start with the basics, the company’s valuation.

GlaxoSmithKline trades at a historic P/E ratio of 13.9, which is below the biotechnology sector average of 17.1. That said, Glaxo’s 10-year average historic P/E is around 13, so based on that the company looks to me to be overvalued.

Nonetheless, Glaxo’s close peers, Shire (LSE: SHP) and AstraZeneca (LSE: AZN) (NYSE: AZN.US) trade at historic P/Es of 30 and 8 respectively. So all in all, it’s difficult to establish a correct value for the company.

Balance sheet

  Net-debt-to-assets Interest cover by operating profit
GlaxoSmithKline 34% 10x
AstraZeneca 5% 18x
Shire 5%

Unfortunately, compared to its closest peers it would appear that Glaxo has the highest net debt as a percentage of its assets. In addition, Glaxo’s net debt has expanded a compounded 40% since the beginning of 2008, from around £10 billion to £14.1 billion. In comparison, peer AstraZeneca has reduced net debt by 70% over the same period.

Nonetheless, at the end of 2012 Glaxo had £4.1 billion in cash on its balance sheet, just enough to cover all of its short-term debt falling due within the year. 

Company’s performance

  Earnings growth past five years Net profit margin
GlaxoSmithKline 8% 16%
AstraZeneca 26% 14%
Shire 317% 13%

Rising debt is commonly indicative of a company that is investing for growth, however, this does not seem to be the case for Glaxo. Indeed, Glaxo’s earnings growth during the past five years seriously lags its three closest peers, as shown above.

Furthermore, the company’s net profit margin has recently fallen from a high of 20%, which was seen back during 2011.


  Current Dividend Yield Current dividend cover Projected annual dividend growth for next two years.
GlaxoSmithKline 4.7% 1.5 6%
AstraZeneca 5.5% 2.3 2%
Shire 0.4% 7.7 38%
Sector average 4.5% 1.3  

Once again, Glaxo lags its closest peer AstraZeneca when it comes to dividends paid out to shareholders.

Granted, Glaxo’s dividend growth is expected to outpace that of AstraZeneca during the next two years. However, AstraZeneca’s stronger dividend yield and the fact that the payout is covered nearly two-and-a-half times by earnings gives me more confidence in AstraZeneca’s payout. 

Foolish summary

All in all, Glaxo’s higher than average level of debt and slow earnings growth over the past five years are causes for concern. 

So overall, I feel that GlaxoSmithKline is a much weaker share than its peers. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

> Rupert does not own any share mentioned in this article. The Motley Fool has recommended GlaxoSmithKline.